Drug

Zofran

Many of the estimated 85 percent of pregnant women who experience some form of morning sickness will use an anti-nausea medication. 

While some drugs provide relief, others can pose risks in vitro. Zofran birth defects may include cleft lip, craniosynostosis, and congenital malformations. 

Introduced

1991

Treats

Nausea

Side Effects

Birth defects

Read more about Zofran

A newborn baby on a bed representing the Zofran bellwether delay.

Zofran Bellwether Delay Pushes Proceedin...

James Parker · June 29, 2020

The multidistrict Zofran litigation has been further delayed to 2021 due to coronavirus concerns.

Legal Developments
A mother holding her child's hand, representing delays to Zofran bellweather.

Zofran Bellwether Delay Halts Litigatory...

James Parker · March 27, 2020

The first bellwether trial in the multidistrict litigation involving Zofran, an anti-nausea medication that may cause birth defects, has been indefinitely postponed.

Legal Developments
Pregnant woman taking Zofran for nausea representing the 500 cases pending against GlaxoSmithKline.

Hundreds of Cases Against Zofran Manufac...

Nicole Knight · March 13, 2020

More than 500 cases are pending against GlaxoSmithKline, claiming the drugmaker aggressively marketed Zofran to pregnant women without informing them of the potential risk of birth defects.

Legal Developments
Photo of baby feet to suggest birth defects in Zofran litigation which are being disputed, despite removal of one supplemental study in October

Birth Defects in Zofran Litigation Disputed, Despite Evidence Removed

James Parker · November 13, 2019

Recent litigation on Zofran has called into question expert testimony, which was removed from the evidence indicating that Zofran causes birth defects when used by pregnant women. Drug manufacturer, GlaxoSmithKline denies that causation of complications beyond heart defects and cleft palate can be proved. Though five cases were removed from the compilation of suits against GSK, the court proceedings wage on -- calling into question whether or not GSK should be required to update their product labeling with an adequate warning.

Legal Developments